Corvus Pharmaceuticals CRVS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's accrued expenses?
- Corvus Pharmaceuticals (CRVS) reported accrued expenses of $6.99M in Q1 2026.
- How has Corvus Pharmaceuticals's accrued expenses changed year-over-year?
- Corvus Pharmaceuticals's accrued expenses increased by 80.4% year-over-year, from $3.87M to $6.99M.
- What is the long-term trend for Corvus Pharmaceuticals's accrued expenses?
- Over 2 years (2023 to 2025), Corvus Pharmaceuticals's accrued expenses has grown at a 27.8% compound annual growth rate (CAGR), from $3.97M to $6.49M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.